Entrar/Registro  
INICIO ENGLISH
 
Medicina Interna de México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Medicina Interna de México >Año 2013, No. 2


Calvo-Colindrez JE, Duarte-Mote J, Lee Eng-Castro VE, Espinosa-López RF, Romero-Figueroa S, Sánchez-Rojas G
Hiperglucemia por estrés
Med Int Mex 2013; 29 (2)

Idioma: Español
Referencias bibliográficas: 44
Paginas: 164-170
Archivo PDF: 290.39 Kb.

[Texto completo - PDF]

RESUMEN

La hiperglucemia por estrés es la que surge en pacientes ingresados a las unidades de cuidados intensivos con valores previos de glucosa normal. La hiperglucemia es común en pacientes con enfermedades catabólicas, en quienes empeora su pronóstico. En los pacientes quirúrgicos la hiperglucemia se asocia con riesgo creciente de complicaciones infecciosas; la evidencia indirecta indica que el mantenimiento de un estado euglucémico disminuye el riesgo de infección. Las causas de la hiperglucemia por estrés incluyen: concentración excesiva de hormonas contrareguladoras (glucagón, hormona de crecimiento, catecolamina y glucocorticoides endógenos o exógenos), tisulares o plasmáticas de citocinas (particularmente factor alfa de necrosis tumoral [TNalpha] e interleucina-1). Los pacientes con apoyo alimenticio excesivo, sobre todo intravenoso, son particularmente propensos a la hiperglucemia. La insulina sigue siendo el patrón de referencia en el tratamiento de la hiperglucemia, aunque la evidencia que documenta la ventaja clínica de la terapia agresiva de la insulina en las unidades de cuidados intensivos es escasa, sí ha resultado benéfica para los pacientes quirúrgicos tratados en unidades de cuidados intensivos.


Palabras clave: hiperglucemia por estrés, hormonas contrareguladoras.


REFERENCIAS

  1. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care? J Clin Invest 2004;114:1187-1195.

  2. Manzanares W, Aramendi I. Hiperglucemia de estrés y su control con insulina en el paciente crítico: evidencia actual. Med Intensiva 2009.

  3. Fahy BG, Sheehy AM, Coursin DB. Glucose control in the intensive care unit. Crit Care Med 2009;31:1769-1776.

  4. Ellger B, Debaveye Y, Vanhorebeek I, Langouche L, Giulietti A, Van Etten E, et al. Survival benefits of intensive insulin therapy in critical illness: Impact of maintaining normoglycemia versus glycemia-independent actions of insulin. Diabetes 2006;55: 1096-1105.

  5. Aggarwal BB, Kohr WJ,Hass PE, et al. Human tumor necrosis factor: production, purification, and characterization. J Biol Chem 1985;260:2345-2354.

  6. Corstjens AM, Van der Horst IC, Zijlstra JG, Groeneveld AB, Zijlstra F, Tulleken JE, et al. Hyperglycaemia in critically ill patients: Marker or mediator of mortality? Crit Care 2006;10:216.

  7. Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem 1987;262:6951-6954.

  8. Van Deventer SJ. Tumour necrosis factor and Crohn’s disease. Gut 1997;40:443-448.

  9. Kreutziger J, Wenzel V, Kurz A, Constantinescu MA. Admission blood glucose is an independent predictive factor for hospital mortality in polytraumatised patients. Intensive Care Med 2009;35:1234-1239.

  10. Atreya IR, Atreya MF. NF- kβ in inflammatory bowel disease. Journal of Internal Medicine 263:591-596.

  11. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-1367.

  12. Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 2004;79:992-1000.

  13. McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycaemia. Crit Care Clin 2001;17:107-124.

  14. Van den Berghe G, et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 1999;84:1311-1323.

  15. Van den Berghe G, et al. Paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. J Clin Endocrinol Metab 2000;85:183-192.

  16. Wolfe RR, Durkot MJ, Allsop JR, Burke JF. Glucose metabolism in severely burned patients. Metabolism 1979;28:210-220.

  17. Wolfe RR, Herndon DN, Jahoor F, Miyoshi H, Wolfe M. Effects of severe burn injury on substrate cycling by glucose and fatty acids. N Engl J Med 1987;317:403-408.

  18. Mizock BA. Alterations in carbohydrate metabolism during stress: a review of the literature. Am J Med 1995;98:75-84.

  19. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 2002;5:551-559.

  20. Marette A. Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. Curr Opin Clin Nutr Metab Care 2002;5:377-383.

  21. Senn JJ, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin dependent insulin resistance in hepatocytes. J Biol Chem 2003;278:13740-13746.

  22. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002;277:42394-42398.

  23. McCowen KC, et al. Sustained endotoxemia leads to marked down-regulation of early steps in the insulin-signaling cascade. Crit Care Med 2001;29:839-846.

  24. Jiang ZY, et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999;104:447-457.

  25. Devos P, Chiolero R, Van den Berghe G, Preiser JC. Glucose, insulin and myocardial ischemia. Curr Opin Clin Nutr Metab Care 2006;9:131-139.

  26. Rovilas A, Kotsou S. The influence of hyperglycemia on neurological outcome in patients with severe head injury. Neurosurgery 2000;46:335-342.

  27. Oddo M, Schmidt JM, Mayer S, Chiolero RL. Glucose control after severe brain injury. Curr Opin Clin Nutr Metab Care 2008;11:134-139.

  28. Van den Berghe G, Wilmer A, MilantsI, Wouters PJ, Bouckaert B, Bruyninckx F, et al. Intensive insulin therapy in mixed medical/ surgical intensive care units: Benefit versus harm. Diabetes 2006;55:3151-3159.

  29. Reed CC, Stewart RM, Sherman M, Myers JG, Corneille MG, Larson N, et al. Intensive insulin protocol improves glucose control and is associated with a reduction in intensive care unit mortality. J Am Surg Coll 2007;204:1048-1054.

  30. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283-1297.

  31. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al. Intensive insulin therapy and pent starch resuscitation in severe sepsis. N Engl J Med 2008;358:125-139.

  32. Preiser JC, Devos P, Ruiz-Santana S, Mélot C, Annane D, Groeneveld J, et al. A prospective randomized multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: The Glu Control Study. Intensive Care Med 2009;35:1738-1748.

  33. Arabi YM, Dabbagh OC, Tamim HM, Al-Shimemeri AA, Memish ZA, Haddad SH, e t al. Intensive versus conventional insulin therapy: A randomized controlled trial in medical and surgical critically ill patients. Crit Care Med 2008;36:3190-3197.

  34. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock. Crit Care Med 2008;36:296-327.

  35. Krinsley JS, Preiser JC. Moving beyond tight glucose control to safe effective glucose control. Crit Care 2008;12:149.

  36. Griesdale DEG, De Souza RJ, Van Dam RM, Heyland DK, Cook DJ, Malhotra A, et al. Intensive insulin therapy and mortality among critically ill patients: A meta-analysis including NICE- SUGAR study data. CMAJ 2009;180:821-827.

  37. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on in patient glycemic control. Diabetes Care 2009;32:1119-1131.

  38. Shepherd PR, Kahn BB. Glucose transporters and insulin action implications for insulin resistance and diabetes mellitus. N Engl J Med 1999;341:248-257.

  39. Pekala P, Marlow M, Heuvelman D, Connolly D. Regulation of hexose transport in aortic endothelial cells by vascular permeability factor and tumor necrosis factor-alpha, but not by insulin. J Biol Chem 1990;265:18051-1854.

  40. Shikhman AR, Brinson DC, Valbracht J, Lotz MK. Cytokine regulation of facilitated glucose transport in human articular chondrocytes. J Immunol 2001;167:7001-7008.

  41. Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 2006;212:167-78.

  42. Marik PE, Raghavan M. Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 2004;30:748-756.

  43. Pekala P, Marlow M, Heuvelman D, Connolly D. Regulation of hexose transport in aortic endothelial cells by vascular permeability factor and tumor necrosis factor-alpha, but not by insulin. J Biol Chem 1990;265:18051-18054.

  44. Sanchez-Alvarez R, Tabernero A, Medina JM. Endothelin-1 stimulates the translocation and upregulation of both glucose transporter and hexokinase in astrocytes: relationship with gap junctional communication. J. Neurochem 2004; 89:703-714.



>Revistas >Medicina Interna de México >Año2013, No. 2
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019